<DOC>
	<DOCNO>NCT00493636</DOCNO>
	<brief_summary>The study conduct compare progression-free survival patient treat sorafenib gemcitabine/capecitabine versus patient treat placebo gemcitabine/capecitabine locally advance metastatic breast cancer progress follow treatment bevacizumab-containing regimen .</brief_summary>
	<brief_title>1st 2nd Line MBC ( Metastatic Breast Cancer ) With Previous Avastin ( Bevacizumab ) Therapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast . Measurable evaluable locally advanced metastatic disease . Age ≥18 year . Disease progression treatment bevacizumabcontaining regimen adjuvant firstline metastatic setting . Patients must discontinue chemotherapy least 3 week prior randomization . No one prior chemotherapy regimen locally advance metastatic disease . Prior hormonal therapy allow provide discontinue prior randomization . Prior radiation therapy allow must complete least 3 week prior randomization . Previously radiate area ( ) must site disease . ECOG Performance Status 0 1 . Adequate bone marrow , liver , renal function Women childbearing potential must negative serum pregnancy test perform within 7 day prior randomization , must agree use adequate contraception prior study entry , duration study participation 28 day last study drug dosing . Patients must able willing sign write informed consent . Patients must able swallow retain oral medication . Patients breast cancer overexpressing human epidermal growth factor receptor 2 ( HER2 ) ( gene amplification FISH 3+ overexpression immunohistochemistry ) . Patients unknown HER2 status eligible . Patients active brain metastasis . Major surgery , open biopsy , significant traumatic injury within 4 week randomization . Prior use gemcitabine/capecitabine sorafenib . Evidence history bleed diathesis coagulopathy . Serious , nonhealing wound , ulcer , bone fracture . Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result . Use cytochrome P450 enzymeinducing antiepileptic drug allow . Clinically significant cardiac disease Uncontrolled hypertension Thrombolic , embolic , venous , arterial event cerebrovascular accident include transient ischemic attack within past 6 month . Pulmonary hemorrhage/bleeding event &gt; NCICTCAE Grade 2 within 4 week randomization . Any hemorrhage/bleeding event ≥ NCICTCAE Grade 3 within 4 week randomization . Active clinically serious infection &gt; NCICTCAE Grade 2 . Known HIV infection chronic hepatitis B C ( safety effectiveness sorafenib patient population study ) . Previous concurrent cancer distinct primary site histology breast cancer EXCEPT cervical cancer insitu , treat basal cell carcinoma , superficial bladder tumor [ Ta Tis ] cancer curatively treat &gt; 5 year prior randomization . Known suspected allergy sorafenib gemcitabine/capecitabine . Prior concurrent use St. John 's Wort rifampin ( rifampicin ) within 3 week randomization . Concurrent anticancer therapy gemcitabine/capecitabine sorafenib/placebo . Prior treatment agent target VEGF VEGFR ( licensed investigational ) , except bevacizumab . Women pregnant breastfeeding . Use investigational drug within 30 day 5 halflives , whichever longer , precede randomization . Inability comply protocol and/or willing available followup assessment . Any condition investigator 's opinion make patient unsuitable study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Breast Cancer</keyword>
</DOC>